Violin Jonathan 4/A
4/A · Viridian Therapeutics, Inc.\DE · Filed Feb 7, 2023
Insider Transaction Report
Form 4/AAmended
Violin Jonathan
President and COO
Transactions
- Exercise/Conversion
Common Stock
2023-02-02$0.15/sh+50,000$7,500→ 530,905 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-02-02−50,000→ 239,205 totalExercise: $0.15Exp: 2030-09-23→ Common Stock (50,000 underlying) - Sale
Common Stock
2023-02-02$36.80/sh−50,000$1,840,000→ 480,905 total
Footnotes (3)
- [F1]Due to a broker error, the Form 4 filed by the Reporting Person on February 3, 2023 incorrectly reported the source of shares sold on February 2, 2023 pursuant to the Reporting Person's Rule 10b5-1 trading plan. This amendment reflects the exercise of stock options for 50,000 shares of common stock, which were the source of the shares sold.
- [F2]This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]The option vested 25% on September 23, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.